AI Engines For more Details: Perplexity Kagi Labs You
Antineoplastic Activity: Etoposide is a cytotoxic agent that interferes with the replication and transcription of DNA in rapidly dividing cells, including cancer cells. It is effective against a wide range of cancers, including small cell lung cancer, testicular cancer, lymphomas, leukemias, and certain types of solid tumors.
Treatment of Small Cell Lung Cancer: Etoposide is commonly used in combination with other chemotherapy agents for the treatment of small cell lung cancer (SCLC). It is often administered in combination with cisplatin or carboplatin as part of first-line chemotherapy regimens for SCLC.
Treatment of Testicular Cancer: Etoposide is an essential component of chemotherapy regimens used for the treatment of testicular cancer, including both seminoma and non-seminoma types. It may be used in combination with other chemotherapy drugs such as cisplatin and bleomycin.
Treatment of Lymphomas and Leukemias: Etoposide is used in the treatment of various types of lymphomas and leukemias, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). It may be administered as part of combination chemotherapy regimens.
Mechanism of Action: Etoposide exerts its anticancer effects by inhibiting the enzyme topoisomerase II, which plays a crucial role in DNA replication and repair. By inhibiting topoisomerase II, etoposide induces DNA strand breaks and prevents DNA from being resealed, ultimately leading to cell death.
Administration: Etoposide is typically administered intravenously in a hospital or clinical setting. It may also be given orally in certain cases. The dosage and schedule of etoposide administration depend on various factors, including the type and stage of cancer being treated, the patient's overall health, and the presence of other medical conditions.
Side Effects: Common side effects associated with etoposide treatment include nausea, vomiting, diarrhea, mucositis (inflammation of the mucous membranes), myelosuppression (decreased production of blood cells), hair loss (alopecia), and fatigue. These side effects are usually temporary and reversible after treatment discontinuation.
Bone Marrow Suppression: Etoposide can cause bone marrow suppression, resulting in a decrease in the production of white blood cells, red blood cells, and platelets. This may increase the risk of infections, anemia, and bleeding. Regular monitoring of blood cell counts is essential during etoposide treatment.
Infusion Reactions: Infusion reactions, including hypersensitivity reactions and anaphylaxis, may occur during or shortly after etoposide administration. Patients should be closely monitored for signs of infusion reactions, and appropriate supportive care should be provided as needed.
Other Adverse Effects: Rare but serious adverse effects of etoposide include secondary malignancies, allergic reactions, liver toxicity, kidney toxicity, and neurotoxicity. Patients should be monitored closely for these potential complications during etoposide therapy.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0 | 0 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.7 | 0.8 | 3.63 |
| Age-Related Macular Degeneration and Glaucoma | 1 | 0.3 | 2.33 |
| Allergic Rhinitis (Hay Fever) | 2.1 | 1.5 | 0.4 |
| Allergies | 5.4 | 2.5 | 1.16 |
| Allergy to milk products | 1.5 | 0.8 | 0.88 |
| Alopecia (Hair Loss) | 2.3 | 2.3 | |
| Alzheimer's disease | 3.4 | 7 | -1.06 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 1 | 1.3 |
| Ankylosing spondylitis | 3.7 | 1.9 | 0.95 |
| Anorexia Nervosa | 0.3 | 2.6 | -7.67 |
| Antiphospholipid syndrome (APS) | 2 | 0 | 0 |
| Asthma | 1.5 | 0.8 | 0.88 |
| Atherosclerosis | 1.5 | 2.1 | -0.4 |
| Atrial fibrillation | 3.7 | 1 | 2.7 |
| Autism | 11.3 | 8.4 | 0.35 |
| Barrett esophagus cancer | 0.2 | 0.5 | -1.5 |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Bipolar Disorder | 1.1 | 1.8 | -0.64 |
| Brain Trauma | 0.8 | 0.6 | 0.33 |
| Carcinoma | 3.7 | 2.6 | 0.42 |
| Celiac Disease | 1.9 | 2.5 | -0.32 |
| Cerebral Palsy | 1.4 | 1.6 | -0.14 |
| Chronic Fatigue Syndrome | 5.7 | 7 | -0.23 |
| Chronic Kidney Disease | 3 | 2.6 | 0.15 |
| Chronic Lyme | 0.6 | -0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.7 | 1.1 | 1.45 |
| Chronic Urticaria (Hives) | 1.6 | 0.6 | 1.67 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1.9 | -0.36 |
| Colorectal Cancer | 4.5 | 1.3 | 2.46 |
| Constipation | 1.3 | 1 | 0.3 |
| Coronary artery disease | 2.4 | 1 | 1.4 |
| COVID-19 | 10.3 | 13.9 | -0.35 |
| Crohn's Disease | 7.6 | 5.7 | 0.33 |
| cystic fibrosis | 0.6 | 0.9 | -0.5 |
| deep vein thrombosis | 0.6 | 1.4 | -1.33 |
| Depression | 10.2 | 9.6 | 0.06 |
| Dermatomyositis | 0.5 | 0.3 | 0.67 |
| Eczema | 1.2 | 2.8 | -1.33 |
| Endometriosis | 3.3 | 0.5 | 5.6 |
| Eosinophilic Esophagitis | 0.2 | 0.2 | |
| Epilepsy | 2.9 | 1.8 | 0.61 |
| Fibromyalgia | 3.4 | 2.1 | 0.62 |
| Functional constipation / chronic idiopathic constipation | 4.9 | 3.4 | 0.44 |
| gallstone disease (gsd) | 2.4 | 1.1 | 1.18 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.6 | 1.5 | 0.07 |
| Generalized anxiety disorder | 2.3 | 1.7 | 0.35 |
| giant cell arteritis | 0.5 | -0.5 | |
| Glioblastoma | 0.5 | -0.5 | |
| Gout | 0.5 | -0.5 | |
| Graves' disease | 1.2 | 2 | -0.67 |
| Halitosis | 0.4 | 0.5 | -0.25 |
| Hashimoto's thyroiditis | 3 | 0.5 | 5 |
| Hidradenitis Suppurativa | 0.8 | 0.8 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 3.3 | 1.5 | 1.2 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.1 | 4 |
| hyperglycemia | 0.2 | 1.4 | -6 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.5 | 0.8 |
| hypersomnia | 0.5 | -0.5 | |
| hypertension (High Blood Pressure | 2.4 | 5 | -1.08 |
| Hypothyroidism | 1.6 | -1.6 | |
| Hypoxia | 0.5 | 0.5 | |
| IgA nephropathy (IgAN) | 2.3 | -2.3 | |
| Inflammatory Bowel Disease | 5.7 | 9 | -0.58 |
| Insomnia | 1.1 | 0.7 | 0.57 |
| Intelligence | 1.2 | 1.2 | |
| Intracranial aneurysms | 1.3 | 0.5 | 1.6 |
| Irritable Bowel Syndrome | 2.7 | 2.5 | 0.08 |
| Liver Cirrhosis | 4.7 | 3.5 | 0.34 |
| Long COVID | 8.5 | 8.8 | -0.04 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.2 | 1.6 | -7 |
| ME/CFS with IBS | 2 | 3.4 | -0.7 |
| ME/CFS without IBS | 3.1 | 2.8 | 0.11 |
| Menopause | 1.2 | 1.2 | |
| Metabolic Syndrome | 8.4 | 8.5 | -0.01 |
| Mood Disorders | 12.8 | 9.9 | 0.29 |
| multiple chemical sensitivity [MCS] | 1.6 | 0.5 | 2.2 |
| Multiple Sclerosis | 6.2 | 5.8 | 0.07 |
| Multiple system atrophy (MSA) | 2.2 | 1.2 | 0.83 |
| Neuropathy (all types) | 1.1 | 0.2 | 4.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.7 | 5.3 | -0.96 |
| NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
| Obesity | 9.9 | 5.6 | 0.77 |
| obsessive-compulsive disorder | 6 | 4.6 | 0.3 |
| Osteoarthritis | 3.2 | 0.4 | 7 |
| Osteoporosis | 1.6 | 0.8 | 1 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 3.1 | 4.9 | -0.58 |
| Polycystic ovary syndrome | 2.9 | 2.2 | 0.32 |
| Postural orthostatic tachycardia syndrome | 0.5 | 0.8 | -0.6 |
| Premenstrual dysphoric disorder | 1.3 | 0.3 | 3.33 |
| primary biliary cholangitis | 0.5 | 0.7 | -0.4 |
| Psoriasis | 5.2 | 2.4 | 1.17 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.4 | 3.7 | 1 |
| Rosacea | 1.7 | 1 | 0.7 |
| Schizophrenia | 5.7 | 2.7 | 1.11 |
| scoliosis | 0.5 | 0.6 | -0.2 |
| Sjögren syndrome | 1.5 | 3.4 | -1.27 |
| Sleep Apnea | 2 | 2 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.2 | 4.5 |
| Stress / posttraumatic stress disorder | 2.9 | 2.8 | 0.04 |
| Systemic Lupus Erythematosus | 4.2 | 1.8 | 1.33 |
| Tic Disorder | 1.3 | 1.3 | 0 |
| Tourette syndrome | 0.1 | 0.1 | 0 |
| Type 1 Diabetes | 3.2 | 3.5 | -0.09 |
| Type 2 Diabetes | 8.8 | 6.8 | 0.29 |
| Ulcerative colitis | 3.5 | 3.6 | -0.03 |
| Unhealthy Ageing | 7.6 | 2.4 | 2.17 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.